Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.42 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1652104 | 0.91 | PTGDR2 (0.71) | PTGDR2TBXA2RPTGDRCTNNB1TCF7L2 | |
| SCHEMBL8738513 | 0.89 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRCTNNB1TCF7L2 | |
| SCHEMBL8737655 | 0.84 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRCTNNB1TCF7L2 | |
| SCHEMBL1652154 | 0.84 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRALDH1A1NR1H4 | |
| SCHEMBL1654290 | 0.83 | PTGDR2 (0.68) | PTGDR2TBXA2RPTGDRCTNNB1TCF7L2 | |
| SCHEMBL15746418 | 0.83 | PTGDR2 (0.71) | PTGDR2TBXA2RPTGDRNR1H4 | |
| SCHEMBL15750176 | 0.82 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRCTNNB1TCF7L2 | |
| SCHEMBL10206862 | 0.82 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRCTNNB1TCF7L2 | |
| SCHEMBL1652371 | 0.82 | PTGDR2 (0.64) | PTGDR2TBXA2RPTGDRMEN1KMT2A | |
| SCHEMBL1652434 | 0.81 | PTGDR2 (0.66) | PTGDR2TBXA2RPTGDRCTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129820-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | HRH2, HRH1, HRH4 | PTGDR2 11/4885TBXA2R 20/4885PTGDR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.